These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 18375007)

  • 1. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
    Murata R; Tsujitani M; Horsman MR
    Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
    Horsman MR; Overgaard J
    Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Horsman MR
    Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response.
    Horsman MR; Nielsen T; Østergaard L; Overgaard J
    Acta Oncol; 2006; 45(7):876-80. PubMed ID: 16982553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective enhancement of radiation response in a C3H mammary carcinoma by cisplatin.
    Overgaard J; Khan AR
    Cancer Treat Rep; 1981; 65(5-6):501-3. PubMed ID: 7195305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice.
    Schütze C; Bergmann R; Yaromina A; Hessel F; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2007 Jun; 83(3):311-5. PubMed ID: 17502117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
    Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
    Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
    Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation.
    Schreiber A; Krause M; Zips D; Dörfler A; Richter K; Vettermann S; Petersen C; Beuthien-Baumann B; Thümmler D; Baumann M
    Strahlenther Onkol; 2004 Jun; 180(6):375-82. PubMed ID: 15175873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental studies on the radiation-modifying effect of bleomycin in malignant and normal mouse tissue in vivo.
    Molin J; Søgaard PE; Overgaard J
    Cancer Treat Rep; 1981; 65(7-8):583-9. PubMed ID: 6166372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells.
    Horsman MR; Chaplin DJ; Overgaard J
    Cancer Res; 1990 Dec; 50(23):7430-6. PubMed ID: 2147577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitizing effect of nicotinamide and carbogen combined in fractionated pions or x-rays in SCCVII tumors.
    Ohizumi Y; Lam GK; Pickles T; Fryer C; Chaplin DJ
    Radiat Med; 1995; 13(6):291-5. PubMed ID: 8850370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual damage in mouse lungs at long intervals after cyclophosphamide treatment.
    Travis EL; Bucci L; Fang MZ
    Cancer Res; 1990 Apr; 50(7):2139-45. PubMed ID: 2317805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC.
    Petersen C; Zips D; Krause M; Völkel W; Thames HD; Baumann M
    Radiother Oncol; 2005 Mar; 74(3):331-6. PubMed ID: 15763315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL; Horsman MR
    Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen cathode measurements and radiation response in tumour-bearing mice treated with misonidazole.
    Davies RW; Hall WS
    Br J Cancer Suppl; 1978 Jun; 3():154-8. PubMed ID: 277216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of local tumour control by misonidazole and hyperthermia.
    Stone HB
    Br J Cancer Suppl; 1978 Jun; 3():178-83. PubMed ID: 277222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
    Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
    Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
    Kirichenko AV; Rich TA; Newman RA; Travis EL
    Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.